Bristol-Myers Squibb Company carries a market capitalization of 70.70B, placing it among publicly traded companies globally. Its enterprise value stands at 122.60B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 70.70B |
| Enterprise Value | 122.60B |
Bristol-Myers Squibb Company currently has 2.04B shares outstanding.
| Shares Outstanding | 2.04B |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Bristol-Myers Squibb Company trades at a trailing price-to-earnings ratio of 11.91. The price-to-sales ratio is 1.79, and the price-to-book ratio stands at 4.66.
| PE Ratio | 11.91 |
| PS Ratio | 1.79 |
| PB Ratio | 4.66 |
| P/TBV Ratio | -4.30 |
| P/FCF Ratio | 6.53 |
| P/OCF Ratio | 6.51 |
On an enterprise value basis, Bristol-Myers Squibb Company trades at an EV/EBITDA multiple of 7.13 and an EV/FCF ratio of 8.35. The EV/Sales ratio of 2.53 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 9.02 provides insight into valuation relative to core operating earnings.
| EV / Sales | 2.53 |
| EV / EBITDA | 7.13 |
| EV / EBIT | 9.02 |
| EV / FCF | 8.35 |
Bristol-Myers Squibb Company maintains a current ratio of 1.42, meaning it holds 1.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 230.96, indicating elevated leverage, while an interest coverage ratio of 9.50 demonstrates adequate ability to service its debt obligations.
| Current Ratio | 1.42 |
| Quick Ratio | 1.18 |
| Debt / Equity | 230.96 |
| Debt / EBITDA | 2.70 |
| Interest Coverage | 9.50 |
Bristol-Myers Squibb Company posts a return on equity of 41.60 and a return on invested capital of 15.17.
| Return on Equity (ROE) | 41.60 |
| Return on Assets (ROA) | 8.13 |
| Return on Invested Capital (ROIC) | 15.17 |
| Return on Capital Employed (ROCE) | 13.03 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 5.28 |
Over the trailing twelve months, Bristol-Myers Squibb Company has paid 2.32B in income taxes, reflecting an effective tax rate of 24.22.
| Income Tax | 2.32B |
| Effective Tax Rate | 24.22 |
Bristol-Myers Squibb Company's stock has declined approximately -0.49122807% over the past 52 weeks. The 50-day moving average sits at 43.75, while the 200-day moving average is 43.75.
| Beta (5Y) | N/A |
| 52-Week Price Change | -0.49122807% |
| 50-Day Moving Average | 43.75 |
| 200-Day Moving Average | 43.75 |
| Average Volume (20 Days) | N/A |
Over the trailing twelve months, Bristol-Myers Squibb Company generated 48.48B in revenue and converted that into 7.28B in net income, yielding earnings per share of 3.56. EBITDA reached 17.18B, while operating income came in at 13.59B.
| Revenue | 48.48B |
| Gross Profit | 34.16B |
| Operating Income | 13.59B |
| Pretax Income | 9.60B |
| Net Income | 7.28B |
| EBITDA | 17.18B |
| EBIT | 13.59B |
| Earnings Per Share (EPS) | 3.56 |
Bristol-Myers Squibb Company holds 10.49B in cash and equivalents against 46.43B in total debt, resulting in a net debt position of 34.89B. Total book value stands at 18.58B, with working capital of 8.05B providing operational flexibility.
| Cash & Cash Equivalents | 10.49B |
| Total Debt | 46.43B |
| Net Debt | 34.89B |
| Equity (Book Value) | 18.58B |
| Book Value Per Share | 9.12 |
| Working Capital | 8.05B |
Bristol-Myers Squibb Company produced 13.31B in operating cash flow over the past twelve months.
| Operating Cash Flow | 13.31B |
| Capital Expenditures | N/A |
| Free Cash Flow | 13.31B |
| FCF Per Share | 6.53 |
Bristol-Myers Squibb Company operates with a gross margin of 70.45, reflecting its pricing power and cost economics. The operating margin of 28.03 and net profit margin of 15.01 provide insight into operational efficiency.
| Gross Margin | 70.45 |
| Operating Margin | 28.03 |
| Pretax Margin | 19.79 |
| Profit Margin | 15.01 |
| EBITDA Margin | 35.44 |
The company's payout ratio of 69.77 indicates the proportion of earnings distributed to shareholders.
| Dividend Per Share | 2.49 |
| Dividend Yield | N/A |
| Payout Ratio | 69.77 |
| Shareholder Yield | 12.60 |
| FCF Yield | 15.32 |
Bristol-Myers Squibb Company posts an Altman Z-Score of 3.56, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 3.56 |